Social, economic, and health utility considerations in the treatment of overactive bladder

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn. 2002;21:167–178.
   PubMed Web of Science ®Google Scholar
• Chu FM, Dmochowski R. Pathophysiology of overactive bladder. Am J Med. 2006;119(3 Suppl 1):3–8.
   PubMedGoogle Scholar
• Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001;87:760–766.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327–336.
   PubMed Web of Science ®Google Scholar
• Tubaro A, Palleschi G. Overactive bladder: epidemiology and social impact. Curr Opin Obstet Gynecol. 2005;17:507–511.
   PubMed Web of Science ®Google Scholar
• Serels S. The wet patient: understanding patients with overactive bladder and incontinence. Curr Med Res Opin. 2004;20:791–801.
   PubMed Web of Science ®Google Scholar
• Ricci JA, Baggish JS, Hunt TL, et al. Coping strategies and health care-seeking behavior in a US national sample of adults with symptoms suggestive of overactive bladder. Clin Ther. 2001;23:1245–1259.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in 5 countries: results of the EPIC study. Eur Urol. 2006;50:1306–1315.
   PubMed Web of Science ®Google Scholar
• Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am JManag Care. 2000;6:S574–S579.
   PubMed Web of Science ®Google Scholar
• Norton PA, MacDonald LD, Sedgwick PM, Stanton SL. Distress and delay associated with urinary incontinence, frequency, and urgency in women. BMJ. 1988;297:1187–1189.
   PubMed Web of Science ®Google Scholar
• Abrams P, Kelleher CJ, Kerr LA, Rogers RG. Overactive bladder significantly affects quality of life. Am J Manag Care. 2000;6(11 Suppl): S580–S590.
   PubMed Web of Science ®Google Scholar
• Johannesson M, O’Conor RM, Kobelt-Nguyen G, Mattiasson A. Willingness to pay for reduced incontinence symptoms. Br J Urol. 1997;80:557–562.
   PubMedGoogle Scholar
• Lenderking WR, Nackley JF, Anderson RB, et al. A review of the quality-of-life aspects of urinary urge incontinence. Pharmacoeconomics. 1996;9:11–23.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Kopp Z, Abrams P, Cardozo L. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006;97:96–100.
   PubMed Web of Science ®Google Scholar
• Darkow T, Fontes CL, Williamson TE. Costs associated with the management of overactive bladder and related comorbidities. Pharmacotherapy. 2005;25:511–519.
   PubMed Web of Science ®Google Scholar
• Zorn BH, Montgomery H, Pieper K, et al. Urinary incontinence and depression. J Urol. 1999;162:82–84.
   Web of Science ®Google Scholar
• Brown JS, Subak LL, Gras J, et al. Urge incontinence: The patient’s perspective. J Women’s Health. 1998;7:1263–1269.
   PubMed Web of Science ®Google Scholar
• Stewart W, Van Rooyen JB, Cundiff G, et al. Prevalence and burden of overactive in the United States. World J Urol. 2003;20:327–336.
   PubMed Web of Science ®Google Scholar
• Robinson D, Pearce KF, Preisser JS, et al. Relationship between patient reports of urinary incontinence symptoms and quality of life measures. Obstet Gynecol. 1998;91:224–228.
   PubMed Web of Science ®Google Scholar
• Liberman JN, Hunt TL, Stewart WF, et al. Health-related quality of life among adults with symptoms of overactive bladder: results from a US community-based survey. Urology. 2001;57:1044–1050.
   PubMed Web of Science ®Google Scholar
• Michel MC, de la Rosette JJ, Piro M, Schneider T. Comparison of symptom severity and treatment response in patients with incontinent and continent overactive bladder. Eur Urol. 2005;48:110–115.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey. Value Health. 2004;7:455–463.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101:1388–1395.
   PubMed Web of Science ®Google Scholar
• Ponholzer A, Temml C, Obermayr R, et al. Association between lower urinary tract symptoms and erectile dysfunction. Urology. 2004;64:772–776.
   PubMed Web of Science ®Google Scholar
• Frankel SJ, Donovan JL, Peters TI, et al. Sexual dysfunction in men with lower urinary tract symptoms. J Clin Epidemiol. 1998;51:677–685.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Reilly K, et al. Overactive bladder is associated with erectile dysfunction and reduced sexual quality of life in men. J Sex Med. 2008;5:2904–2910.
   PubMed Web of Science ®Google Scholar
• Aslan G, Cavus E, Karas H, Oner O, Duran F, Esen A. Association between lower urinary tract symptoms and erectile dysfunction. Arch Androl. 2006;52:155–162.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Margolis MK, Jumadilova Z, Bavendam T, Mueller E, Rogers R. Overactive bladder and women’s sexual health: what is the impact? J Sex Med. 2007;4:656–666.
   PubMed Web of Science ®Google Scholar
• Yip SK, Chan A, Pang S, et al. The impact of urodynamic stress incontinence and detrusor overactivity on marital relationship and sexual function. Am J Obstet Gynecol. 2003;188:1244–1248.
   PubMed Web of Science ®Google Scholar
• Cohen BL, Barboglio P, Gousse A. The impact of lower urinary tract symptoms and urinary incontinence on female sexual dysfunction using a validated instrument. J Sex Med. 2008;5:1418–1423.
   PubMed Web of Science ®Google Scholar
• Irwin DE, Milsom I, Reilly K, et al. Overactive bladder symptoms associated with a negative impact on work productivity: results from the EPIC study. International Continence Society. Christchurch, New Zealand. 2006. URL: http://www.icsoffice.org/publications/2006/pdf/0432.pdf. Accessed Jul 15, 2009.
   Google Scholar
• Sexton CC, Coyne KS, Vats V, et al. Impact of overactive bladder on work productivity in the United States: results from EpiLUTS. Am J Manag Care. 2009;15(4 Suppl):S98–S107.
   PubMedGoogle Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353–365.
   PubMed Web of Science ®Google Scholar
• Coyne KS, Matza LS, Brewster-Jordan J. “We have to stop again?!”: The impact of overactive bladder on family members. Neurourol Urodyn. 2009;28:969–975.
   PubMedGoogle Scholar
• Coyne KS, Matza LS, Brewster-Jordan J, Thompson C, Bavendam T. The psychometric validation of the OAB family impact measure (OAB-FIM). Neurourol Urodynam. 2009. [Epub Mar 9].
   Web of Science ®Google Scholar
• Basra R, Kelleher C. Disease burden of overactive bladder: quality-of-life data assessed using ICI-recommended instruments. Pharmacoeconomic. 2007;25:129–142.
   PubMed Web of Science ®Google Scholar
• Donovan J, Badia X, Corcos J, et al. Committee . 6: symptom and quality of life assessment. In: Abrams P, Cardozo L, Khoury S, et al, (eds): Incontinence. Plymouth, United Kingdom: Plymbridge Distributors, Ltd; 2002:267–316.
   Google Scholar
• Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health. 1999;53:46–50.
   PubMed Web of Science ®Google Scholar
• Komaroff AL, Fagioli LR, Doolittle TH, et al. Health status in patients with chronic fatigue Syndrome and in general population and disease comparison groups. Am J Med. 1996;101:281–290.
   PubMed Web of Science ®Google Scholar
• Kobelt G. Economic consideration and outcome measurement in urge incontinence. J Urol. 1997;50(Suppl 6A):100–107.
   Google Scholar
• Currie CJ, McEwan P, Poole CD, Odeyemi IA, Datta SN, Morgan CL. The impact of the overactive bladder on health-related utility and quality of life. BJU Int. 2006;97:1267–1272.
   PubMed Web of Science ®Google Scholar
• Johannesson M, O’Conor RM, Kobelt-Nguyen G, Mattiasson A. Willingness to pay for reduced incontinence symptoms. Br J Urol. 1997;80:557–562.
   PubMedGoogle Scholar
• O’Conor RM, Johannesson M, Hass SL, Kobelt-Nguyen G. Urge incontinence. Quality of life and patients’ valuation of symptom reduction. Pharmacoeconomics. 1998;14:531–539.
   PubMed Web of Science ®Google Scholar
• Coyne K, Revicki D, Hunt T, et al. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q. Qual Life Res. 2002;11:563–574.
   PubMed Web of Science ®Google Scholar
• Abrams P, Avery K, Gardener N, et al. The International Consultation on Incontinence Modular Questionnaire: www.iciq.net. J Urol. 2006;175:1063–1066.
   Google Scholar
• Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res. 2005;14:849–855.
   PubMed Web of Science ®Google Scholar
• Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol. 1997;104:988–993.
   PubMedGoogle Scholar
• Reese PR, Pleil AM, Okano GJ, et al. Multinational study of reliability and validity of the King’s Health Questionnaire in patients with overactive bladder. Qual Life Res. 2003;12:427–442.
   PubMed Web of Science ®Google Scholar
• Jackson S, Donovan J, Brookes S, Eckford S, Swithinbank L, Abrams P. The Bristol Female Lower Urinary Tract Symptoms questionnaire: development and psychometric testing. BJU. 1996;77:805–812.
   Google Scholar
• Donovan J, Abrams P, Peters T, et al. The ICS-‘BPH’ study: the psychometric validity and reliability of the ICSmale questionnaire. BJU. 1996;77:554–562.
   Google Scholar
• Shumaker SA, Wyman JF, Uebersax JS, et al. Health-related quality of life measures for women with urinary incontinence: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program in Women (CPW) Research Group. Qual Life Res. 1994;3:291–306.
   Google Scholar
• Wagner TH, Patrick DL, Bavendam TG, Martin ML, Buesching DP. Quality of life of persons with urinary incontinence: development of a new measure. Urology. 1996;47:67–71.
   PubMed Web of Science ®Google Scholar
• Matza LS, Thompson CL, Krasnow J, Brewster-Jordan J, Zyczynski T, Coyne KS. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ). Neurourol Urodyn. 2005;24:215–225.
   PubMed Web of Science ®Google Scholar
• Matza LS, Zyczynski TM, Bavendam T. A review of quality-of-life questionnaires for urinary incontinence and overactive bladder: which ones to use and why? Curr Urol Rep. 2004;5:336–342.
   PubMedGoogle Scholar
• Wagner TH, Hu TW. Economic costs of urinary incontinence in 1995. Urology. 1998;51:355–361.
   PubMed Web of Science ®Google Scholar
• Akobundu E, Ju J, Blatt L, Mullins CD. Cost-of-illness studies : a review of current methods. Pharmacoeconomics. 2006;24:869–890.
   PubMed Web of Science ®Google Scholar
• Hu TW, Wagner TH. Economic considerations in overactive bladder. Am J Manag Care. 2000;6(11 Suppl):S591–S598.
   PubMed Web of Science ®Google Scholar
• Erdem N, Chu FM. Management of overactive bladder and urge urinary incontinence in the elderly patient. Am J Med. 2006;119(3 Suppl 1):29–36.
   PubMedGoogle Scholar
• Wagg AS, Cardozo L, Chapple C, et al. Overactive bladder syndrome in older people. BJU Int. 2007;99(3):502–509.
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallett D. Employees with overactive bladder: work loss burden. J Occup Environ Med. 2005;47:439–446.
   PubMed Web of Science ®Google Scholar
• Brubaker L, Chapple C, Coyne KS, Kopp Z. Patient-reported outcomes in overactive bladder: importance for determining clinical effectiveness of treatment. Urology. 2006;68(2 Suppl):3–8.
   PubMedGoogle Scholar
• Wilson L, Brown JS, Shin GP, Luc KO, Subak LL. Annual direct cost of urinary incontinence. Obstet Gynecol. 2001;98:398–406.
   PubMed Web of Science ®Google Scholar
• Hu TW, Wagner TH, Bentkover JD, Leblanc K, Zhou SZ, Hunt T. Costs of urinary incontinence and overactive bladder in the United States; a comparative study. Urology. 2004;63:461–465.
   PubMed Web of Science ®Google Scholar
• Hu TW. Impact of urinary incontinence on health-care costs. J Am Geriatr Soc. 1990;38:292–295.
   PubMed Web of Science ®Google Scholar
• Hu TW, Wagner TH, Bentkover JD, et al. Estimated economic costs of overactive bladder in the United States. Urology. 2003;61:1123–1128.
   PubMed Web of Science ®Google Scholar
• MacKay K, Hemmett L. Needs assessment of women with urinary incontinence in a district health authority. Br J Gen Pract. 2001;51:801–804.
   PubMed Web of Science ®Google Scholar
• Hu TW, Wagner TH. Health-related consequences of overactive bladder: an economic perspective. BJU Int. 2005;96(Suppl 1):43–45.
   PubMedGoogle Scholar
• National Institutes of Health. Disease-Specific Estimates of Direct and Indirect Costs of Illness and NIH Support. Bethesda, Maryland, US Public Health Services. 2000. URL: http://ospp.od.nih.gov/ecostudies/ COIreportweb.htm. Accessed Jul 15, 2009.
   Google Scholar
• Onukwugha E, Zuckerman IH, McNally D, Coyne KS, Vats V, Mullins CD. The total economic burden of overactive bladder in the United States: a disease-specific approach. Am J Manag Care. 2009;15(4 Suppl):S90–S97.
   PubMedGoogle Scholar
• Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C. The economic impact of overactive bladder syndrome in six Western countries. BJU Int. 2009;103:202–209.
   PubMed Web of Science ®Google Scholar
• Cartwright R, Renganathan A, Cardozo L. Current management of overactive bladder. Curr Opin Obstet Gynecol. 2008;20:489–495.
   PubMed Web of Science ®Google Scholar
• Ouslander JG. Management of overactive bladder. N Engl J Med. 2004;350:786–799.
   PubMed Web of Science ®Google Scholar
• Bo K, Berghmans LC. Nonpharmacologic treatments for overactive bladder-pelvic floor exercises. Urology. 2000;55:7–11.
   PubMed Web of Science ®Google Scholar
• Brubaker L. Electrical stimulation in overactive bladder. Urology. 2000;55:17–23.
   PubMed Web of Science ®Google Scholar
• Cardozo LD. Biofeedback in overactive bladder. Urology. 2000;55:24–28.
   PubMed Web of Science ®Google Scholar
• Payne CK. Behavioral therapy for overactive bladder. Urology. 2000;55:3–6.
   PubMed Web of Science ®Google Scholar
• Sacco E, Pinto F, Bassi P. Emerging pharmacological targets in overactive bladder therapy: experimental and clinical evidences. Int Urogynecol J Pelvic Floor Dysfunct. 2008;19(4):583–598.
   PubMed Web of Science ®Google Scholar
• Andersson KE. New pharmacologic targets for the treatment of the overactive bladder: an update. Urology. 2004;63(Suppl 3A):32–41.
   PubMed Web of Science ®Google Scholar
• Appell RA. The newer antimuscarinic drugs: bladder control with less dry mouth. Cleve Clin J Med. 2002;69:761–769.
   PubMed Web of Science ®Google Scholar
• Cannon TW, Chancellor MB. Pharmacotherapy of the overactive bladder and advances in drug delivery. Clin Obstet Gynecol. 2002;45:205–217.
   PubMed Web of Science ®Google Scholar
• Katz IR, Sands LP, Bilker W, et al. Identification of medications that cause cognitive impairment in older people: The case of oxybutynin chloride. J Am Geriatr Soc. 1998;46:8–13.
   PubMed Web of Science ®Google Scholar
• Hashim H, Abrams P. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations. Drugs. 2004;64:1643–1656.
   PubMed Web of Science ®Google Scholar
• Drutz H, Appell RA, Gleason D, et al. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunction. 1999;10:283–289.
   PubMedGoogle Scholar
• Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc. 2001;76:358–363.
   PubMed Web of Science ®Google Scholar
• Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, doubleblind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003;78:687–695.
   PubMed Web of Science ®Google Scholar
• Sussman G, Garely A. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: the Antimuscarinic Clinical Effectiveness Trial (ACET). Curr Med Res Opin. 2002;19:177–184.
   Google Scholar
• Haab F, Cardozo L, Chapple C, et al. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome. Eur Urol. 2005;47:376–384.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Martinez-Garcia R, Selvaggi L, et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial. Eur Urol. 2005;48:464–470.
   PubMed Web of Science ®Google Scholar
• Steers W, Corcos J, Foote J, Kralidis G. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int. 2005;95:580–586.
   PubMed Web of Science ®Google Scholar
• Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother. 2008;9:1787–1796.
   PubMed Web of Science ®Google Scholar
• Schurch B, de Seze M, Denys P, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196–200.
   PubMed Web of Science ®Google Scholar
• Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177:2231–2236.
   PubMed Web of Science ®Google Scholar
• Ghei M, Maraj BH, Miller R, et al. Effects of botulinumtoxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol. 2005;174:1873–1877.
   PubMed Web of Science ®Google Scholar
• Sacco E, Paolillo M, Totaro A, et al. Botulinum toxin in the treatment of overactive bladder. Urologia. 2008;75:1–10.
   PubMedGoogle Scholar
• Di Stasi SM, Giannantoni A, Vespasiani G, Navarra P, Capelli G, Massoud R, et al. Intravesical electromotive administration of oxybutynin in patients with detrusor hyperreflexia unresponsive to standard anticholinergic regimens. J Urol. 2001;165:491–498.
   PubMed Web of Science ®Google Scholar
• Gauruder-Burmester A, Biskupskie A, Rosahl A, Tunn R. Electromotive Drug Administration for Treatment of Therapy-Refractory Overactive Bladder. IntBraz J Urol. 2008;34:758–764.
   Google Scholar
• Janknegt RA, Hassouna MM, Siegel SW, et al. Long-term effectiveness of sacral nerve stimulation for refractory urge incontinence. Eur Urol. 2001;39:101–106.
   PubMed Web of Science ®Google Scholar
• Das AK, Carlson AM, Hull M. Improvement in depression and health-related quality of life after sacral nerve stimulation therapy for treatment of voiding dysfunction. Urology. 2004;64:62–68.
   PubMed Web of Science ®Google Scholar
• Hijaz A, Vasavada S. Complications and troubleshooting of sacral neuromodulation therapy. Urol Clin North Am. 2005;32:65–69.
   PubMed Web of Science ®Google Scholar
• Busse R, Orvain J, Velasco M, et al. Best practice in undertaking and reporting health technology assessments. Int J Technol Assess Health Care. 2002;18:361–422.
   PubMed Web of Science ®Google Scholar
• National Institute for Clinical Excellence. Guide to the methods of technology appraisal. NICE. 2004. URL: http://www.nice.org. uk/niceMedia/pdf/TAP_Methods.pdf. Accessed Jul 15, 2009.
   Google Scholar
• Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64:1465–1475.
   PubMed Web of Science ®Google Scholar
• Torrance GW. Measurement of health state utilities for economic appraisal: a review. J Health Econom. 1986;5:1–30.
   PubMed Web of Science ®Google Scholar
• Rodriguez LV, Blander DS, Dorey F, Raz S, Zimmern P. Discrepancy in patient and physician perception of patient’s quality of life related to urinary symptoms. Urology. 2003;62:49–53.
   PubMed Web of Science ®Google Scholar
• Prieto LS. Problems and solutions in calculating quality-adjusted life years (QALYs). Health and Quality of Life Outcomes. 2003;1:80.
   PubMedGoogle Scholar
• Mortimer D, Segal L. Comparing the incomparable? a systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decis Making. 2008;28:66–89.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Jönsson L, Mattiasson A. Cost-effectiveness of new treatments for overactive bladder: the example of tolterodine, a new muscarinic agent: a Markov model. Neurourol Urodyn. 1998;17:599–611.
   PubMed Web of Science ®Google Scholar
• Milsom I, Axelsen S, Kulseng-Hansen S, Mattiasson A, Nilsson CG, Wickstrøm J. Cost-effectiveness analysis of solifenacin flexible dosing in patients with overactive bladder symptoms in four Nordic countries. Acta Obstet Gynecol Scand. 2009;88:693–699.
   PubMed Web of Science ®Google Scholar
• Wu JM, Siddiqui NY, Amundsen CL, Myers ER, Havrilesky LJ, Visco AG. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence. J Urol. 2009;181:2181–2186.
   PubMed Web of Science ®Google Scholar
• Speakman M, Khullar V, Mundy A, Odeyemi I, Bolodeoku J. A costutility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome. Curr Med Res Opin. 2008;24:2173–2179.
   PubMed Web of Science ®Google Scholar
• O’Brien BJ, Goeree R, Bernard L, Rosner A, Williamson T. Cost-Effectiveness of tolterodine for patients with urge incontinence who discontinue initial therapy with oxybutynin: a Canadian perspective. Clin Ther. 2001;23:2038–2049.
   PubMed Web of Science ®Google Scholar
• Arnold D, Girling A, Stevens A, Lilford R. Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis. BMJ. 2009;339: b2688.
   Google Scholar
• Brazier J, Roberts J, Deverill M. The estimation of a utility based algorithm from the SF-36 Health Survey. J Health Econ. 2002;21:271–292.
   PubMed Web of Science ®Google Scholar
• EuroQol Group. URL: http://www.euroqol.org/home.html. Accessed Jul 15, 2009.
   Google Scholar
• EuroQoL Group. EuroQoL – a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.
   PubMed Web of Science ®Google Scholar
• Brazier J, Deverill M, Green C, et al. A review of the use of health status measures in economic evaluation. Health Technol Assess. 1999;3:1–164.
   Google Scholar
• Yang Y, Brazier J, Tsuchiya A, Coyne, Karin P. Estimating a Preference-Based Single Index from the Overactive Bladder Questionnaire. Value Health. 2009;12:159–166.
   PubMed Web of Science ®Google Scholar
• Kok ET, McDonnell J, Stolk EA, Stoevelaar HJ, Busschbach JJ. The valuation of the International Prostate Symptom Score (IPSS) for use in economic evaluations. Eur Urol. 2002;42:491–497.
   PubMed Web of Science ®Google Scholar
• Stolk EA, Busschbach JJ. Validity and feasibility of the use of condition-specific outcome measures in economic evaluation. Qual Life Res. 2003;12:363–371.
   PubMed Web of Science ®Google Scholar
• Brazier JE, Czoski-Murray C, Roberts J, et al. Estimation of a preference-based index from a condition specific measure: the King’s Health Questionnaire. Med Decis Making. 2008;28:113–126.
   PubMed Web of Science ®Google Scholar
• Revicki DA, Leidy NK, Brennan F, et al. Development and preliminary validation of the multiattribute rhinitis symptom utility index. Qual Life Res. 1998;7:693–702.
   PubMed Web of Science ®Google Scholar
• Dowie J. Decision validity should determine whether generic or condition-specific HRQOL measure is used in health care decisions. Health Econ. 2002;11:1–8.
   PubMed Web of Science ®Google Scholar
• Capri S, Sormani MP, Lavezzari M, Velona T. Willingness to pay for reduced urge incontinence. Value in Health. 2000;3:304–305.
   Google Scholar
• Hughes DA, Dubois D. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. Pharmacoeconomics. 2004;22:1047–1059.
   PubMed Web of Science ®Google Scholar
• Getsios D, Caro JJ, Ishak KJ, El-Hadi W, Payne K. Canadian economic comparison of extended-release oxybutynin and immediate-release tolterodine in the treatment of overactive bladder. Clin Ther. 2004;26:431–438.
   PubMed Web of Science ®Google Scholar
• Varadharajan S, Jumadilova Z, Girase P, Ollendorf DA. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder. Am J Manag Care. 2005 ;11(4 Suppl): S140-S149.
   Web of Science ®Google Scholar
• Arikian SR, Casciano J, Doyle JJ, Tarride JE, Casciano RN. A phar-macoeconomic evaluation of two new products for the treatment of overactive bladder. Manag Care Interface. 2000;13:88–94.
   PubMedGoogle Scholar
• Guest JF, Abegunde D, Ruiz FJ. Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria. Clin Drug Investig. 2004;24:305–321.
   PubMed Web of Science ®Google Scholar
• Getsios D, El-Hadi W, Caro I, Caro JJ. Pharmacological management of overactive bladder: a systematic and critical review of published economic evaluations. Pharmacoeconomics. 2005;23:995–1006.
   PubMed Web of Science ®Google Scholar
• Ko Y, Malone DC, Armstrong EP. Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder. Pharmacotherapy. 2006;26:1694–1702.
   PubMed Web of Science ®Google Scholar
• Pelletier EM, Vats V, Clemens JQ. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder. Am J Manag Care. 2009;15(4 Suppl):S108–S114.
   PubMedGoogle Scholar
• Sangster P, Kalsi V. Health economics and intradetrusor injections of botulinum for the treatment of detrusor overactivity. BJU Int. 2008;102(Suppl 1):17–19.
   PubMedGoogle Scholar
• Kalsi V, Popat RB, Apostolidis A, et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol. 2005;49:519–527.
   PubMed Web of Science ®Google Scholar
• Wu JM, Siddiqui NY, Amundsen CL, Myers ER, Havrilesky LJ, Visco AG. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence. J Urol. 2009;181:2181–2186.
   PubMed Web of Science ®Google Scholar
• Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis. Health Econ. 2004;13:437–452.
   PubMed Web of Science ®Google Scholar
• Aboseif SR, Kim DH, Rieder JM, et al. Sacral neuromodulation: cost considerations and clinical benefits. Urology. 2007;70:1069–1074.
   PubMed Web of Science ®Google Scholar
• Brown MM, Brown GC, Sharma S, et al. Health care economic analyses and value-based medicine. Surv Ophthalmol. 2003;48:204–223.
   PubMed Web of Science ®Google Scholar
• Schabert VF, Bavendam T, Goldberg EL, Trocio JN, Brubaker L. Challenges for managing overactive bladder and guidance for patient support. Am J Manag Care. 2009;15(4 Suppl):S118–S122.
   PubMedGoogle Scholar
• Kobelt G, Kirchberger I, Malone-Lee J. Quality-of-life aspects of the overactive bladder and the effect of treatment with tolterodine. BJU Int. 1999;83:583–590.
   PubMed Web of Science ®Google Scholar